Conduit Pharmaceuticals CDT 深 沪
等待开盘 10-07 09:30:00 美东时间
0.9301
+0.012
+1.35%
华盛通- 最 高0.94
- 今 开0.90
- 成交量 90.16万股
- 最 低 0.851
- 昨 收 0.9177
- 总市值 104.59万
- 52周最高 22327.50
- 市盈率 静 --
- 换手率 80.18%
- 52周最低 0.8502
- 委 比 11.06%
- 总股本 112.45万
- 历史最高 1875000000.00
- 量 比 1.75
- 振 幅 9.70%
- 历史最低 0.851
- 每 手 1
- 风险率 7607.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
Sarborg Limited has filed new intellectual property applying quantum sampling to disease biology and drug discovery. CDT Equity Inc. holds a 22.7% stake in Sarborg, which recently raised capital at $125,000 per share, valuing the company at approximately $709 million. Sarborg's novel approach focuses on disease gene regulation networks, utilizing quantum computing to address complex biological problems. The model has been applied to 150 disease n...
09-29 11:00
CDT Equity Inc. Announces Reverse Stock Split
CDT Equity Inc. announced a 1-for-25 reverse stock split to maintain compliance with Nasdaq's bid-price rule. Effective September 28, 2026, every 25 shares will combine into one, reducing outstanding shares to approximately 1,013,515. The stock will continue trading under "CDT" with a new CUSIP number, and no fractional shares will be issued. The transfer agent, Continental Stock Transfer & Trust Co., will handle the exchange.
09-25 12:10
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
CDT Equity Inc. partners with QIMA Life Sciences to explore autoimmune skin disease treatments. Initial studies focus on tapinarof (VTAMA®) for psoriasis and atopic dermatitis, aiming to develop a second-generation product with enhanced efficacy. CDT also investigates tapinarof combinations for vitiligo, addressing significant unmet needs in this market. The partnership leverages QIMA’s access to human skin samples for clinically relevant data, a...
09-18 10:30
CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
CDT Equity Inc. highlights Sarborg Limited's successful application of its patented Signature Intelligence and quantum computing models to mental health and neuropsychiatric drug discovery. With over 1 billion people globally affected by mental disorders and an estimated $1 trillion annual economic cost, Sarborg's proprietary database of disease signatures, combined with advanced computing, identifies potential therapeutic relationships. CDT owns...
09-10 11:00
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
CDT Equity Inc. (NASDAQ: CDT) reported 13,693,866 outstanding shares as of August 31, 2026, with a market capitalization of approximately $23.0 million. The company's stockholders' equity was $103 million as of June 30, 2026, and it has resolved all outstanding deficiencies with The Nasdaq Stock Market LLC. CDT Equity is a biopharmaceutical development company focused on advancing therapeutic assets through scientific innovation and strategic par...
09-02 09:00
CDT Equity Appoints James Bligh As CEO
CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced the appointment of James Bligh, co-founder of Conduit Pharmaceuticals Limited (now CDT), as Chief Executive Officer. Mr. Bligh brings extensive public-markets, corporate finance and transaction experience to the role and will lead...
09-01 20:15
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
CDT Equity Inc. appoints James Bligh as CEO, while Dr. Andrew Regan becomes CEO of Sarborg. Bligh, co-founder of Conduit Pharmaceuticals, brings extensive experience in corporate finance and transactions. CDT has made strategic investments, including a 22% stake in Sarborg, a quantum signature intelligence business. Both leaders aim to drive growth and value creation for their respective companies.
09-01 12:00
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
CDT Equity Inc. announced new solid forms and alternative crystal structures of its drug compounds, offering improved stability, solubility, and manufacturability. These forms are patent-protected and could support new formulations for specific patient needs, potentially extending the commercial life of the assets. The company has filed patents for new potential uses of its existing assets, targeting underserved patient groups and diseases with l...
08-28 09:00
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
CDT Equity Inc. has entered into a SAFE note agreement with Pep'd Inc., a US-based peptide company, to expand its exposure to the growing US peptide market. The SAFE will convert into shares of Safe Preferred Stock upon Pep'd's equity financing, subject to a $10 million valuation cap. CDT aims to leverage AI-enabled platforms for therapeutic development and explore opportunities in the peptide sector. The US peptide market is projected to grow si...
08-25 09:00
CDT Equity Inc. Announces Reverse Stock Split
CDT Equity Inc. announces a 1-for-10 reverse stock split to maintain compliance with Nasdaq's bid-price rule. Effective July 17, 2026, every 10 shares will combine into 1 share, with trading resuming on July 20 under the same ticker "CDT." The company's common stock will have a new CUSIP number, and outstanding shares will reduce to approximately 631,077. Fractional shares will be settled with cash. The reverse split aims to ensure continued list...
07-16 12:00
